Study: Off-label marketing tactics tough to stop

Off-label drug marketing is common, a new study from PLoS Medicine finds. However, it's difficult to police the most common forms of off-label promotion. Report

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.